

Harald Mischak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7335317/publications.pdf>

Version: 2024-02-01

424
papers

30,879
citations

2970

93
h-index

6294

158
g-index

462
all docs

462
docs citations

462
times ranked

19429
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of the chronic kidney disease urinary proteomic predictor CKD273 with clinical risk factors of graft failure in kidney allograft recipients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2014-2021.	0.4	4
2	Increased Collagen Turnover Is a Feature of Fibromuscular Dysplasia and Associated With Hypertrophic Radial Remodeling: A Pilot, Urine Proteomic Study. <i>Hypertension</i> , 2022, 79, 93-103.	1.3	4
3	The novel proteomic signature for cardiac allograft vasculopathy. <i>ESC Heart Failure</i> , 2022, 9, 1216-1227.	1.4	8
4	Proteomic Analysis of Mouse Kidney Tissue Associates Peroxisomal Dysfunction with Early Diabetic Kidney Disease. <i>Biomedicines</i> , 2022, 10, 216.	1.4	4
5	Interview with Harald Mischak. <i>Proteomics</i> , 2022, 22, e2100390.	1.3	0
6	Collagen-Derived Peptides in CKD: A Link to Fibrosis. <i>Toxins</i> , 2022, 14, 10.	1.5	15
7	A Model to Detect Significant Prostate Cancer Integrating Urinary Peptide and Extracellular Vesicle RNA Data. <i>Cancers</i> , 2022, 14, 1995.	1.7	5
8	Gene Expression Monotonicity across Bladder Cancer Stages Informs on the Molecular Pathogenesis and Identifies a Prognostic Eight-Gene Signature. <i>Cancers</i> , 2022, 14, 2542.	1.7	3
9	Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancer. <i>World Journal of Urology</i> , 2022, 40, 2195-2203.	1.2	4
10	Peptides in Plasma, Urine, and Dialysate: Toward Unravelling Renal Peptide Handling. <i>Proteomics - Clinical Applications</i> , 2021, 15, e2000029.	0.8	22
11	Amniotic fluid peptides predict postnatal kidney survival in developmental kidney disease. <i>Kidney International</i> , 2021, 99, 737-749.	2.6	15
12	Value of Urine Peptides in Assessing Kidney and Cardiovascular Disease. <i>Proteomics - Clinical Applications</i> , 2021, 15, e2000027.	0.8	29
13	Urinary fetuin-A peptides as a new marker for impaired kidney function in patients with type 2 diabetes. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 269-276.	1.4	11
14	The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 811-818.	0.4	26
15	Understanding glomerular diseases through proteomics. <i>Expert Review of Proteomics</i> , 2021, 18, 137-157.	1.3	7
16	A robust machine learning framework to identify signatures for frailty: a nested case-control study in four aging European cohorts. <i>GeroScience</i> , 2021, 43, 1317-1329.	2.1	31
17	Data Sharing Under the General Data Protection Regulation. <i>Hypertension</i> , 2021, 77, 1029-1035.	1.3	47
18	Proteomic Biomarkers in the Cardiorenal Syndrome: Toward Deciphering Molecular Pathophysiology. <i>American Journal of Hypertension</i> , 2021, 34, 669-679.	1.0	10

#	ARTICLE	IF	CITATIONS
19	Biomarkers for early detection of kidney disease: a call for pathophysiological relevance. <i>Kidney International</i> , 2021, 99, 1240-1241.	2.6	2
20	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1875-1887.	2.9	37
21	A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients. <i>EClinicalMedicine</i> , 2021, 36, 100883.	3.2	28
22	A Novel Urinary Proteomics Classifier for Non-Invasive Evaluation of Interstitial Fibrosis and Tubular Atrophy in Chronic Kidney Disease. <i>Proteomes</i> , 2021, 9, 32.	1.7	21
23	Urinary peptidome and diabetic retinopathy in the DIRECTâ€Protect 1 and 2 trials. <i>Diabetic Medicine</i> , 2021, 38, e14634.	1.2	7
24	Pathophysiological Implications of Urinary Peptides in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3786.	1.7	7
25	Urine peptidome analysis in cardiorenal syndrome reflects molecular processes. <i>Scientific Reports</i> , 2021, 11, 16219.	1.6	7
26	Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol. <i>Blood Pressure</i> , 2021, 30, 269-281.	0.7	8
27	CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVIDâ€19: A potential link to molecular pathophysiology?. <i>Proteomics</i> , 2021, 21, e2100133.	1.3	16
28	SGLT2â€inhibition reverts urinary peptide changes associated with severe COVIDâ€19: An inâ€silico proofâ€ofâ€principle of proteomicsâ€based drug repurposing. <i>Proteomics</i> , 2021, 21, e2100160.	1.3	3
29	Serum and urinary biomarkers of collagen typeâ€I turnover predict prognosis in patients with heart failure. <i>Clinical and Translational Medicine</i> , 2021, 11, e267.	1.7	10
30	Urine proteomics for prediction of disease progression in patients with IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 42-52.	0.4	36
31	Urinary peptidomic profiles to address age-related disabilities: a prospective population study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e690-e703.	2.0	17
32	Reproducibility Evaluation of Urinary Peptide Detection Using CE-MS. <i>Molecules</i> , 2021, 26, 7260.	1.7	28
33	Molecular Mapping of Urinary Complement Peptides in Kidney Diseases. <i>Proteomes</i> , 2021, 9, 49.	1.7	5
34	Proteomeâ€based classification of Nonmuscle Invasive Bladder Cancer. <i>International Journal of Cancer</i> , 2020, 146, 281-294.	2.3	35
35	A novel urinary biomarker predicts 1-year mortality after discharge from intensive care. <i>Critical Care</i> , 2020, 24, 10.	2.5	16
36	Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma. <i>Journal of Biomedical Science</i> , 2020, 27, 13.	2.6	19

#	ARTICLE	IF	CITATIONS
37	Multi-omics applied to fibromuscular dysplasia: first steps on a new research avenue. Cardiovascular Research, 2020, 116, 4-5.	1.8	4
38	Urinary Peptides Significantly Associate with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study. Proteomics, 2020, 20, 2000202.	1.3	27
39	Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosis: A multicentre study. EBioMedicine, 2020, 62, 103083.	2.7	10
40	Drug repurposing in oncology. Lancet Oncology, The, 2020, 21, e543.	5.1	20
41	A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients' Omics Signatures. Cancers, 2020, 12, 3519.	1.7	12
42	MO041URINE PROTEOMICS FOR PREDICTION OF DISEASE PROGRESSION IN PATIENTS WITH IGA NEPHROPATHY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	7
43	P0724ASSOCIATIONS OF URINARY POLYMERIC IMMUNOGLOBULIN RECEPTOR PEPTIDES IN THE CONTEXT OF CARDIO-RENAL SYNDROM. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
44	Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 383-400.	0.4	4
45	Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer. Diagnostics, 2020, 10, 658.	1.3	7
46	Connectivity mapping of glomerular proteins identifies dimethylaminoparthenolide as a new inhibitor of diabetic kidney disease. Scientific Reports, 2020, 10, 14898.	1.6	14
47	P0652THYMOSIN BETA 4 AND KIDNEY FUNCTION: AN INVERSE RELATIONSHIP?. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
48	Proteomic characterization of obesity-related nephropathy. CKJ: Clinical Kidney Journal, 2020, 13, 684-692.	1.4	14
49	Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation. Diagnostics, 2020, 10, 655.	1.3	12
50	Associations of urinary polymeric immunoglobulin receptor peptides in the context of cardio-renal syndrome. Scientific Reports, 2020, 10, 8291.	1.6	10
51	The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. ESC Heart Failure, 2020, 7, 1595-1604.	1.4	15
52	Multiplexed MRM-based protein quantification of putative prognostic biomarkers for chronic kidney disease progression in plasma. Scientific Reports, 2020, 10, 4815.	1.6	17
53	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 301-312.	5.5	166
54	Re-analysis of Peptidomic analysis of cartilage and subchondral bone in OA patients. European Journal of Clinical Investigation, 2020, 50, e13240.	1.7	1

#	ARTICLE	IF	CITATIONS
55	Datasharing: Obsolete? Impossible in times of GDPR ? Or mandatory in science?!. European Journal of Clinical Investigation, 2020, 50, e13244.	1.7	0
56	Proteomics biomarkers for solid tumors: Current status and future prospects. Mass Spectrometry Reviews, 2019, 38, 49-78.	2.8	53
57	Urinary peptidomic biomarkers of renal function in heart transplant recipients. Nephrology Dialysis Transplantation, 2019, 34, 1336-1343.	0.4	10
58	The CKD plasma lipidome varies with disease severity and outcome. Journal of Clinical Lipidology, 2019, 13, 176-185.e8.	0.6	13
59	Emerging urine-based proteomic biomarkers as valuable tools in the management of chronic kidney disease. Expert Review of Molecular Diagnostics, 2019, 19, 853-856.	1.5	9
60	Detecting clinically significant prostate cancer with urine: A multivariable risk model integrating urinary proteomic and cell-free RNA data. European Urology Supplements, 2019, 18, e3150.	0.1	1
61	Proteomics and personalized medicine: a focus on kidney disease. Expert Review of Proteomics, 2019, 16, 773-782.	1.3	15
62	Urinary peptide panel for prognostic assessment of bladder cancer relapse. Scientific Reports, 2019, 9, 7635.	1.6	12
63	CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. British Journal of Cancer, 2019, 120, 1120-1128.	2.9	25
64	Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future. Electrophoresis, 2019, 40, 2294-2308.	1.3	89
65	Proteomics in Drug Development: The Dawn of a New Era?. Proteomics - Clinical Applications, 2019, 13, e1800087.	0.8	48
66	Proteomics based identification of KDM5 histone demethylases associated with cardiovascular disease. EBioMedicine, 2019, 41, 91-104.	2.7	23
67	Urinary proteome signature of Renal Cysts and Diabetes syndrome in children. Scientific Reports, 2019, 9, 2225.	1.6	15
68	Clinical Proteomics on the Path Toward Implementation: First Promises Delivered. Proteomics - Clinical Applications, 2019, 13, e1800094.	0.8	3
69	MAGE genes in the kidney: identification of MAGED2 as upregulated during kidney injury and in stressed tubular cells. Nephrology Dialysis Transplantation, 2019, 34, 1498-1507.	0.4	16
70	Urinary proteomic biomarkers in oncology: ready for implementation?. Expert Review of Proteomics, 2019, 16, 49-63.	1.3	4
71	CKD273 Enables Efficient Prediction of Diabetic Nephropathy in Nonalbuminuric Patients. Diabetes Care, 2019, 42, e4-e5.	4.3	30
72	Urinary proteomics to diagnose chronic active antibody-mediated rejection in pediatric kidney transplantation - a pilot study. Transplant International, 2019, 32, 28-37.	0.8	20

#	ARTICLE	IF	CITATIONS
73	Urinary Glycopeptide Analysis for the Investigation of Novel Biomarkers. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800111.	0.8	17
74	Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment. <i>JCI Insight</i> , 2019, 4, .	2.3	25
75	Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, gfw406.	0.4	29
76	Comparison of Urine and Plasma Peptidome Indicates Selectivity in Renal Peptide Handling. <i>Proteomics - Clinical Applications</i> , 2018, 12, e1700163.	0.8	38
77	Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease. <i>Scientific Reports</i> , 2018, 8, 5584.	1.6	19
78	Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria. <i>Cardiovascular Diabetology</i> , 2018, 17, 50.	2.7	36
79	Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease. <i>Journal of Translational Medicine</i> , 2018, 16, 104.	1.8	48
80	Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 438-447.e4.	2.3	20
81	Urinary CE-MS peptide marker pattern for detection of solid tumors. <i>Scientific Reports</i> , 2018, 8, 5227.	1.6	28
82	Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus. <i>Lupus</i> , 2018, 27, 6-16.	0.8	30
83	Removal of Cell-Activating Substances Using Dialyzers With Various Permeability Profiles. <i>Artificial Organs</i> , 2018, 42, 78-87.	1.0	8
84	Clinical Proteomics for Precision Medicine: The Bladder Cancer Case. <i>Proteomics - Clinical Applications</i> , 2018, 12, 1700074.	0.8	21
85	Urinary peptidomics in kidney disease and drug research. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 259-268.	2.5	24
86	Biomarkers to Assess Right Heart Pressures in Recipients of a Heart Transplant: A Proof-of-Concept Study. <i>Transplantation Direct</i> , 2018, 4, e346.	0.8	7
87	Urinary proteomic signatures associated with β -blockade and heart rate in heart transplant recipients. <i>PLoS ONE</i> , 2018, 13, e0204439.	1.1	3
88	FP754A URINARY PROTEOME-BASED CLASSIFIER FOR THE DIAGNOSIS OF CHRONIC KIDNEY DISEASE IN CHILDREN. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i300-i301.	0.4	0
89	Novel Urinary Biomarkers For Improved Prediction Of Progressive eGFR Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease. <i>Scientific Reports</i> , 2018, 8, 15940.	1.6	52
90	Kidney protective effects of baroreflex activation therapy in patients with resistant hypertension. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1519-1526.	1.0	10

#	ARTICLE	IF	CITATIONS
91	Promise and Implementation of Proteomic Prostate Cancer Biomarkers. <i>Diagnostics</i> , 2018, 8, 57.	1.3	9
92	Characteristics of high- and low-risk individuals in the <sc>PRIORITY</sc> study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. <i>Diabetic Medicine</i> , 2018, 35, 1375-1382.	1.2	24
93	Clinical Proteomics: Closing the Gap from Discovery to Implementation. <i>Proteomics</i> , 2018, 18, e1700463.	1.3	24
94	WILEY SERIES ON MASS SPECTROMETRY. , 2018, , b1-b2.		0
95	Urinary peptide biomarker panel associated with an improvement in estimated glomerular filtration rate in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 751-759.	0.4	15
96	A urinary proteome-based classifier for the early detection of decline in glomerular filtration. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw239.	0.4	73
97	Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw243.	0.4	25
98	Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw292.	0.4	66
99	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw337.	0.4	62
100	Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. <i>Scientific Reports</i> , 2017, 7, 40473.	1.6	32
101	Tissue Proteomics in Vascular Disease. <i>Methods in Molecular Biology</i> , 2017, 1527, 53-60.	0.4	1
102	A Urinary Fragment of Mucin-1 Subunit 1 Is a Novel Biomarker Associated With Renal Dysfunction in the General Population. <i>Kidney International Reports</i> , 2017, 2, 811-820.	0.4	24
103	Proteomics in cardiovascular disease: recent progress and clinical implication and implementation. <i>Expert Review of Proteomics</i> , 2017, 14, 117-136.	1.3	34
104	The long path towards implementation of clinical proteomics: Exemplified based on CKD273. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1600104.	0.8	27
105	Alterations in urinary collagen peptides in lupus nephritis subjects correlate with renal dysfunction and renal histopathology. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1468-1477.	0.4	16
106	Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis. <i>Scientific Reports</i> , 2017, 7, 9091.	1.6	16
107	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. <i>Kidney International Reports</i> , 2017, 2, 1066-1075.	0.4	77
108	Novel Urinary Peptidomic Classifier Predicts Incident Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	30

#	ARTICLE	IF	CITATIONS
109	Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?. Scientific Reports, 2017, 7, 16915.	1.6	67
110	Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy. Scientific Reports, 2017, 7, 15160.	1.6	28
111	A combined bile and urine proteomic test for cholangiocarcinoma diagnosis in patients with biliary strictures of unknown origin. United European Gastroenterology Journal, 2017, 5, 668-676.	1.6	23
112	Mitogen-Activated Protein Kinase 14 Promotes AKI. Journal of the American Society of Nephrology: JASN, 2017, 28, 823-836.	3.0	38
113	Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease. CKJ: Clinical Kidney Journal, 2017, 10, 192-201.	1.4	77
114	Clinical Proteomics in Kidney Disease: From Discovery to Clinical Application. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2017, 38, 39-54.	0.2	5
115	Does urinary peptide content differ between COPD patients with and without inherited alpha-1 antitrypsin deficiency?. International Journal of COPD, 2017, Volume 12, 829-837.	0.9	12
116	The use of urinary proteomics in the assessment of suitability of mouse models for ageing. PLoS ONE, 2017, 12, e0166875.	1.1	17
117	The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. PLoS ONE, 2017, 12, e0186910.	1.1	21
118	Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention. Oncotarget, 2017, 8, 69435-69455.	0.8	27
119	Prediction of acute coronary syndromes by urinary proteome analysis. PLoS ONE, 2017, 12, e0172036.	1.1	30
120	Tomato Juice Consumption Modifies the Urinary Peptide Profile in Sprague-Dawley Rats with Induced Hepatic Steatosis. International Journal of Molecular Sciences, 2016, 17, 1789.	1.8	9
121	Urinary Peptide Analysis Differentiates Pancreatic Cancer From Chronic Pancreatitis. Pancreas, 2016, 45, 1018-1026.	0.5	24
122	Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in Type 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. BMJ Open, 2016, 6, e010310.	0.8	103
123	Comparison of different statistical approaches for urinary peptide biomarker detection in the context of coronary artery disease. BMC Bioinformatics, 2016, 17, 496.	1.2	6
124	Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study. Clinical Cancer Research, 2016, 22, 4077-4086.	3.2	90
125	Development of a MALDI MS-based platform for early detection of acute kidney injury. Proteomics - Clinical Applications, 2016, 10, 732-742.	0.8	13
126	Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. Kidney International, 2016, 90, 1045-1055.	2.6	31

#	ARTICLE	IF	CITATIONS
127	Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of omics findings. <i>Scientific Reports</i> , 2016, 6, 25619.	1.6	12
128	Urinary biomarkers for renal tract malformations. <i>Expert Review of Proteomics</i> , 2016, 13, 1121-1129.	1.3	7
129	BcCluster: A Bladder Cancer Database at the Molecular Level. <i>Bladder Cancer</i> , 2016, 2, 65-76.	0.2	4
130	Urinary proteomics using capillary electrophoresis coupled to mass spectrometry for diagnosis and prognosis in kidney diseases. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 494-501.	1.0	21
131	PeptiCKDb peptide- and protein-centric database for the investigation of genesis and progression of chronic kidney disease. <i>Database: the Journal of Biological Databases and Curation</i> , 2016, 2016, baw128.	1.4	7
132	Urine proteome analysis in heart failure with reduced ejection fraction complicated by chronic kidney disease: feasibility, and clinical and pathogenetic correlates. <i>European Journal of Heart Failure</i> , 2016, 18, 822-829.	2.9	28
133	Urine proteomics in the diagnosis of stable angina. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 70.	0.7	20
134	Urine proteome analysis as a discovery tool in patients with deep vein thrombosis and pulmonary embolism. <i>Proteomics - Clinical Applications</i> , 2016, 10, 574-584.	0.8	17
135	Acute kidney injury prediction in cardiac surgery patients by a urinary peptide pattern: a case-control validation study. <i>Critical Care</i> , 2016, 20, 157.	2.5	24
136	Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease. <i>Diabetologia</i> , 2016, 59, 1819-1831.	2.9	34
137	The role of urinary peptidomics in kidney disease research. <i>Kidney International</i> , 2016, 89, 539-545.	2.6	59
138	Urinary biomarkers to predict CKD: is the future in multi-marker panels?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1373-1375.	0.4	12
139	The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 2003-2011.	0.4	101
140	Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction. <i>PLoS ONE</i> , 2016, 11, e0157167.	1.1	42
141	Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. <i>PLoS ONE</i> , 2016, 11, e0167582.	1.1	22
142	Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca ²⁺ signaling in T24M-based bladder cancer models. <i>Oncotarget</i> , 2016, 7, 70750-70768.	0.8	19
143	Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management. <i>Bioanalysis</i> , 2016, 8, 439-455.	0.6	11
144	Detection of urinary biomarkers in reservoir hosts of leptospirosis by capillary electrophoresis-mass spectrometry. <i>Proteomics - Clinical Applications</i> , 2015, 9, 543-551.	0.8	20

#	ARTICLE	IF	CITATIONS
145	Urinary proteomic biomarkers to predict cardiovascular events. <i>Proteomics - Clinical Applications</i> , 2015, 9, 610-617.	0.8	33
146	Comparison of higher energy collisional dissociation and collision-induced dissociation MS/MS sequencing methods for identification of naturally occurring peptides in human urine. <i>Proteomics - Clinical Applications</i> , 2015, 9, 531-542.	0.8	19
147	Protein Interactome of Muscle Invasive Bladder Cancer. <i>PLoS ONE</i> , 2015, 10, e0116404.	1.1	12
148	Comparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic Analysis. <i>PLoS ONE</i> , 2015, 10, e0137048.	1.1	92
149	FP223 URINARY PEPTIDE-BASED PREDICTION OF PROGRESSION FROM CHRONIC KIDNEY DISEASE STAGE II TO III. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii141-iii141.	0.4	1
150	Developing proteomic biomarkers for bladder cancer: towards clinical application. <i>Nature Reviews Urology</i> , 2015, 12, 317-330.	1.9	69
151	Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment. <i>Sleep Science</i> , 2015, 8, 58-67.	0.4	6
152	Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure. <i>IJC Metabolic & Endocrine</i> , 2015, 6, 5-12.	0.5	19
153	Capillary zone electrophoresis on-line coupled to mass spectrometry: A perspective application for clinical proteomics. <i>Proteomics - Clinical Applications</i> , 2015, 9, 453-468.	0.8	43
154	Proteomic biomarkers in kidney disease: issues in development and implementation. <i>Nature Reviews Nephrology</i> , 2015, 11, 221-232.	4.1	101
155	CE-MS based proteomics in biomarker discovery and clinical application. <i>Proteomics - Clinical Applications</i> , 2015, 9, 322-334.	0.8	68
156	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1999-2010.	3.0	205
157	Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iv86-iv95.	0.4	33
158	New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1842-1852.	0.4	64
159	Urinary Proteome and Systolic Blood Pressure as Predictors of 5-Year Cardiovascular and Cardiac Outcomes in a General Population. <i>Hypertension</i> , 2015, 66, 52-60.	1.3	33
160	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 531-532.	0.4	3
161	Pro: Urine proteomics as a liquid kidney biopsy: no more kidney punctures!. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 532-537.	0.4	52
162	Epidemiologic Design and Analysis for Proteomic Studies: A Primer on -Omic Technologies. <i>American Journal of Epidemiology</i> , 2015, 181, 635-647.	1.6	30

#	ARTICLE	IF	CITATIONS
163	Recent progress in urinary proteome analysis for prostate cancer diagnosis and management. Expert Review of Molecular Diagnostics, 2015, 15, 1539-1554.	1.5	13
164	Body fluid peptide and protein signatures in diabetic kidney diseases. Nephrology Dialysis Transplantation, 2015, 30, iv43-iv53.	0.4	7
165	Two-group comparisons of zero-inflated intensity values: the choice of test statistic matters. Bioinformatics, 2015, 31, 2310-2317.	1.8	19
166	Impact of a 6-wk olive oil supplementation in healthy adults on urinary proteomic biomarkers of coronary artery disease, chronic kidney disease, and diabetes (types 1 and 2): a randomized, parallel, controlled, double-blind study. American Journal of Clinical Nutrition, 2015, 101, 44-54.	2.2	58
167	Integrating Proteomics Profiling Data Sets: A Network Perspective. Methods in Molecular Biology, 2015, 1243, 237-253.	0.4	5
168	Proteomic urinary biomarker approach in renal disease: from discovery to implementation. Pediatric Nephrology, 2015, 30, 713-725.	0.9	39
169	Methods in Capillary Electrophoresis Coupled to Mass Spectrometry for the Identification of Clinical Proteomic/Peptidomic Biomarkers in Biofluids. Methods in Molecular Biology, 2015, 1243, 187-205.	0.4	20
170	Comparison of Depletion Strategies for the Enrichment of Low-Abundance Proteins in Urine. PLoS ONE, 2015, 10, e0133773.	1.1	39
171	Identification of ageing-associated naturally occurring peptides in human urine. Oncotarget, 2015, 6, 34106-34117.	0.8	31
172	Diabetische Nephropathie – aktuelle Diagnostik und Therapie mittels Urinproteomanalyse. Nieren- Und Hochdruckkrankheiten, 2015, 44, 1-9.	0.0	2
173	Clinical proteomics in obstetrics and neonatology. Expert Review of Proteomics, 2014, 11, 75-89.	1.3	31
174	Identification of Urinary Peptide Biomarkers Associated with Rheumatoid Arthritis. PLoS ONE, 2014, 9, e104625.	1.1	32
175	Advances in urinary proteome analysis and applications in systems biology. Bioanalysis, 2014, 6, 2549-2569.	0.6	17
176	Urinary proteomics in obstructive sleep apnoea and obesity. European Journal of Clinical Investigation, 2014, 44, 1104-1115.	1.7	14
177	Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. Journal of Proteomics, 2014, 98, 44-58.	1.2	64
178	Urine as a source for clinical proteome analysis: From discovery to clinical application. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 884-898.	1.1	84
179	Comparison of <sc>CE</sc>-<sc>MS</sc>/<sc>MS</sc> and <sc>LC</sc>-<sc>MS</sc>/<sc>MS</sc> sequencing demonstrates significant complementarity in natural peptide identification in human urine. Electrophoresis, 2014, 35, 1060-1064.	1.3	104
180	Proteome-Based Systems Biology Analysis of the Diabetic Mouse Aorta Reveals Major Changes in Fatty Acid Biosynthesis as Potential Hallmark in Diabetes Mellitus-Associated Vascular Disease. Circulation: Cardiovascular Genetics, 2014, 7, 161-170.	5.1	22

#	ARTICLE	IF	CITATIONS
181	Putting value in biomarker research and reporting. <i>Journal of Proteomics</i> , 2014, 96, A1-A3.	1.2	19
182	Plasma and Urinary Amino Acid Metabolomic Profiling in Patients with Different Levels of Kidney Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 37-45.	2.2	155
183	Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications. <i>Bioanalysis</i> , 2014, 6, 247-266.	0.6	20
184	Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation. <i>Leukemia</i> , 2014, 28, 842-852.	3.3	47
185	Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases. <i>Expert Review of Proteomics</i> , 2014, 11, 535-548.	1.3	24
186	Proteome analysis in the assessment of ageing. <i>Ageing Research Reviews</i> , 2014, 18, 74-85.	5.0	18
187	Left ventricular diastolic function in relation to the urinary proteome: A proof-of-concept study in a general population. <i>International Journal of Cardiology</i> , 2014, 176, 158-165.	0.8	44
188	The urinary proteome as correlate and predictor of renal function in a population study. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2260-2268.	0.4	57
189	Proteomics and Metabolomics as Tools to Unravel Novel Culprits and Mechanisms of Uremic Toxicity: Instrument or Hype?. <i>Seminars in Nephrology</i> , 2014, 34, 180-190.	0.6	19
190	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1563-1570.	0.4	106
191	Proteomics of Vitreous Humor of Patients with Exudative Age-Related Macular Degeneration. <i>PLoS ONE</i> , 2014, 9, e96895.	1.1	74
192	Assessment of Metabolomic and Proteomic Biomarkers in Detection and Prognosis of Progression of Renal Function in Chronic Kidney Disease. <i>PLoS ONE</i> , 2014, 9, e96955.	1.1	101
193	The enzymatic activity of the VEGFR2 receptor for the biosynthesis of dinucleoside polyphosphates. <i>Journal of Molecular Medicine</i> , 2013, 91, 1095-1107.	1.7	17
194	IMAC Fractionation in Combination with LC-MS Reveals H2B and NIF-1 Peptides As Potential Bladder Cancer Biomarkers. <i>Journal of Proteome Research</i> , 2013, 12, 3969-3979.	1.8	20
195	Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on bladder cancer. <i>Proteomics - Clinical Applications</i> , 2013, 7, 779-793.	0.8	26
196	A peptidomic approach to biomarker discovery for bovine mastitis. <i>Journal of Proteomics</i> , 2013, 85, 89-98.	1.2	81
197	Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. <i>Electrophoresis</i> , 2013, 34, 1452-1464.	1.3	103
198	Fetal Urinary Peptides to Predict Postnatal Outcome of Renal Disease in Fetuses with Posterior Urethral Valves (PUV). <i>Science Translational Medicine</i> , 2013, 5, 198ra106.	5.8	86

#	ARTICLE	IF	CITATIONS
199	Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. <i>Proteomics</i> , 2013, 13, 2967-2975.	1.3	21
200	Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. <i>Gut</i> , 2013, 62, 122-130.	6.1	131
201	Technical aspects and inter-laboratory variability in native peptide profiling: The CE-MS experience. <i>Clinical Biochemistry</i> , 2013, 46, 432-443.	0.8	181
202	Proteasix: A tool for automated and large-scale prediction of proteases involved in naturally occurring peptide generation. <i>Proteomics</i> , 2013, 13, 1077-1082.	1.3	104
203	A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. <i>Diabetologia</i> , 2013, 56, 259-267.	2.9	128
204	Urinary Proteomics Based on Capillary Electrophoresis Coupled to Mass Spectrometry in Kidney Disease. <i>Methods in Molecular Biology</i> , 2013, 919, 203-213.	0.4	14
205	A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. <i>BMC Systems Biology</i> , 2013, 7, 110.	3.0	34
206	Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study. <i>PLoS ONE</i> , 2013, 8, e53016.	1.1	70
207	Proteomics as a Quality Control Tool of Pharmaceutical Probiotic Bacterial Lysate Products. <i>PLoS ONE</i> , 2013, 8, e66682.	1.1	23
208	Long Term Metabolic Syndrome Induced by a High Fat High Fructose Diet Leads to Minimal Renal Injury in C57BL/6 Mice. <i>PLoS ONE</i> , 2013, 8, e76703.	1.1	50
209	CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis. <i>PLoS ONE</i> , 2013, 8, e62837.	1.1	125
210	Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. <i>European Heart Journal</i> , 2012, 33, 2342-2350.	1.0	79
211	How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS. <i>Proteomics - Clinical Applications</i> , 2012, 6, 437-442.	0.8	22
212	Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy. <i>Diabetes</i> , 2012, 61, 3304-3313.	0.3	221
213	Urine Proteome Analysis Reflects Atherosclerotic Disease in an ApoE ^{-/-} Mouse Model and Allows the Discovery of New Candidate Biomarkers in Mouse and Human Atherosclerosis. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.013847-1-M111.013847-13.	2.5	37
214	A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases. <i>Journal of Proteomics</i> , 2012, 75, 5888-5897.	1.2	58
215	Urinary Proteome Analysis at 5-Year Followup of Patients With Nonoperated Ureteropelvic Junction Obstruction Suggests Ongoing Kidney Remodeling. <i>Journal of Urology</i> , 2012, 187, 1006-1011.	0.2	31
216	Urinary Proteome Analysis to Exclude Severe Vesicoureteral Reflux. <i>Pediatrics</i> , 2012, 129, e356-e363.	1.0	27

#	ARTICLE	IF	CITATIONS
217	Urinary Proteomics to Support Diagnosis of Stroke. PLoS ONE, 2012, 7, e35879.	1.1	34
218	Evaluation of the Zucker Diabetic Fatty (ZDF) Rat as a Model for Human Disease Based on Urinary Peptidomic Profiles. PLoS ONE, 2012, 7, e51334.	1.1	59
219	Performance of different separation methods interfaced in the same MSâ€reflection TOF detector: A comparison of performance between CE versus HPLC for biomarker analysis. Electrophoresis, 2012, 33, 567-574.	1.3	29
220	Implementation of proteomic biomarkers: making it work. European Journal of Clinical Investigation, 2012, 42, 1027-1036.	1.7	151
221	Proteomic Candidate Biomarkers of Drug-Induced Nephrotoxicity in the Rat. PLoS ONE, 2012, 7, e34606.	1.1	24
222	Proteomic biomarkers for the early detection of acute kidney injury. Prilozi / Makedonska Akademija Na Naukite I Umetnostite, Oddelenie Za Bioloiki I Medicinski Nauki = Contributions / Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences, 2012, 33, 27-48.	0.2	8
223	A Pilot Study on the Effect of Short-Term Consumption of a Polyphenol Rich Drink on Biomarkers of Coronary Artery Disease Defined by Urinary Proteomics. Journal of Agricultural and Food Chemistry, 2011, 59, 12850-12857.	2.4	32
224	Clinical application of urinary proteomics/peptidomics. Expert Review of Proteomics, 2011, 8, 615-629.	1.3	55
225	Omicsâ€Bioinformatics in the Context of Clinical Data. Methods in Molecular Biology, 2011, 719, 479-497.	0.4	14
226	A pilot study of urinary peptides as biomarkers for intelligence in old age. Intelligence, 2011, 39, 46-53.	1.6	10
227	Urinary proteomics in the assessment of chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2011, 20, 654-661.	1.0	50
228	CEâ€MS in biomarker discovery, validation, and clinical application. Proteomics - Clinical Applications, 2011, 5, 9-23.	0.8	88
229	Effect of fenofibrate treatment on the low molecular weight urinary proteome of healthy volunteers. Proteomics - Clinical Applications, 2011, 5, 159-166.	0.8	5
230	Diagnosis of subclinical and clinical acute Tâ€cellâ€mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics - Clinical Applications, 2011, 5, 322-333.	0.8	62
231	Renal and Urinary Proteomics. Proteomics - Clinical Applications, 2011, 5, 211-213.	0.8	3
232	Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology, 2011, 53, 875-884.	3.6	143
233	Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. Journal of Hypertension, 2011, 29, 783-790.	0.3	33
234	Urinary Proteomics for Prediction of Preeclampsia. Hypertension, 2011, 57, 561-569.	1.3	129

#	ARTICLE	IF	CITATIONS
235	A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy. PLoS ONE, 2011, 6, e20534.	1.1	22
236	Peptide Fingerprinting of Alzheimer's Disease in Cerebrospinal Fluid: Identification and Prospective Evaluation of New Synaptic Biomarkers. PLoS ONE, 2011, 6, e26540.	1.1	105
237	Urine proteomics in clinical applications: technologies, principal considerations and clinical implementation. Prilozi / Makedonska Akademija Na Naukite I Umetnostite, Oddelenie Za Bioloiki I Medicinski Nauki = Contributions / Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences. 2011, 32, 13-44.	0.2	8
238	Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. Journal of Hypertension, 2010, 28, 2316-2322.	0.3	119
239	Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease. Pediatric Nephrology, 2010, 25, 27-35.	0.9	66
240	Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. Pediatric Nephrology, 2010, 25, 1673-1678.	0.9	58
241	Addressing the Challenge of Defining Valid Proteomic Biomarkers and Classifiers. BMC Bioinformatics, 2010, 11, 594.	1.2	108
242	Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrology, 2010, 11, 29.	0.8	71
243	Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics - Clinical Applications, 2010, 4, 464-478.	0.8	139
244	Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy. PLoS ONE, 2010, 5, e13421.	1.1	117
245	A Novel Cross-talk in Diacylglycerol Signaling. Journal of Biological Chemistry, 2010, 285, 16931-16941.	1.6	17
246	Proteomic biomarkers in diabetic nephropathy—reality or future promise?. Nephrology Dialysis Transplantation, 2010, 25, 2843-2845.	0.4	29
247	Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney International, 2010, 78, 1252-1262.	2.6	116
248	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. Molecular and Cellular Proteomics, 2010, 9, 2424-2437.	2.5	434
249	Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. Science Translational Medicine, 2010, 2, 46ps42.	5.8	273
250	Urinary Proteomics Based on Capillary Electrophoresis-Coupled Mass Spectrometry in Kidney Disease: Discovery and Validation of Biomarkers, and Clinical Application. Advances in Chronic Kidney Disease, 2010, 17, 493-506.	0.6	69
251	Urinary Collagen Fragments Are Significantly Altered in Diabetes: A Link to Pathophysiology. PLoS ONE, 2010, 5, e13051.	1.1	51
252	Evaluation of Urinary Biomarkers for Coronary Artery Disease, Diabetes, and Diabetic Kidney Disease. Diabetes Technology and Therapeutics, 2009, 11, 1-9.	2.4	95

#	ARTICLE	IF	CITATIONS
253	Urinary Proteome Analysis using Capillary Electrophoresis Coupled to Mass Spectrometry: A Powerful Tool in Clinical Diagnosis, Prognosis and Therapy Evaluation. <i>Journal of Medical Biochemistry</i> , 2009, 28, 223-234.	0.7	10
254	Proteome Analysis in Hematology Using Capillary Electrophoresis Coupled On-Line to Mass Spectrometry. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 627-637.	1.1	7
255	Urinary proteome pattern in children with renal Fanconi syndrome. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2161-2169.	0.4	51
256	Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics. <i>Clinical Cancer Research</i> , 2009, 15, 4935-4943.	3.2	97
257	The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. <i>Cellular Signalling</i> , 2009, 21, 1645-1651.	1.7	44
258	Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developments. <i>Mass Spectrometry Reviews</i> , 2009, 28, 703-724.	2.8	175
259	Capillary electrophoresis-mass spectrometry in urinary proteome analysis: current applications and future developments. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 393, 1431-1442.	1.9	41
260	The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. <i>Proteomics</i> , 2009, 9, 2108-2117.	1.3	82
261	Profiling of rat urinary proteomic patterns associated with drug-induced nephrotoxicity using CE coupled with MS as a potential model for detection of drug-induced adverse effects. <i>Proteomics - Clinical Applications</i> , 2009, 3, 1062-1071.	0.8	14
262	2nd Combined Working Group and Management Committee Meeting of Urine and Kidney Proteomics COST Action 29-30 March 2009, Nafplio, Greece. <i>Proteomics - Clinical Applications</i> , 2009, 3, 1017-1022.	0.8	9
263	PROGRESS IN UREMIC TOXIN RESEARCH: The Role of EUTox in Uremic Toxin Research. <i>Seminars in Dialysis</i> , 2009, 22, 323-328.	0.7	27
264	PROGRESS IN UREMIC TOXIN RESEARCH: Proteomics in Uremia and Renal Disease. <i>Seminars in Dialysis</i> , 2009, 22, 409-416.	0.7	18
265	Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system. <i>British Journal of Pharmacology</i> , 2009, 157, 1142-1153.	2.7	60
266	Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2009, 46, 129-152.	2.7	24
267	Evaluation of Urine Proteome Pattern Analysis for Its Potential To Reflect Coronary Artery Atherosclerosis in Symptomatic Patients. <i>Journal of Proteome Research</i> , 2009, 8, 335-345.	1.8	98
268	Proteomics in Gerontology: Current Applications and Future Aspects - A Mini-Review. <i>Gerontology</i> , 2009, 55, 123-137.	1.4	15
269	Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney Disease. <i>Journal of Proteome Research</i> , 2009, 8, 268-281.	1.8	221
270	Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2009, 76, 89-96.	2.6	86

#	ARTICLE	IF	CITATIONS
271	Capillary Electrophoresis Coupled to Mass Spectrometry for Proteomic Profiling of Human Urine and Biomarker Discovery. <i>Methods in Molecular Biology</i> , 2009, 564, 105-121.	0.4	13
272	Identification and Validation of Urinary Biomarkers for Differential Diagnosis and Evaluation of Therapeutic Intervention in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 2296-2307.	2.5	100
273	Technical, bioinformatical and statistical aspects of liquid chromatographyâ€“mass spectrometry (LCâ€“MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: A critical assessment†. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1250-1258.	1.2	80
274	Definition of Valid Proteomic Biomarkers: A Bayesian Solution. <i>Lecture Notes in Computer Science</i> , 2009, , 137-149.	1.0	5
275	Proteomics as a New Tool for Biomarker-Discovery in Neuropsychiatric Disorders. , 2009, , 103-111.		0
276	Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. <i>World Journal of Urology</i> , 2008, 26, 67-74.	1.2	22
277	Discovery and validation of urinary biomarkers for prostate cancer. <i>Proteomics - Clinical Applications</i> , 2008, 2, 556-570.	0.8	133
278	The urinary proteome in diabetes and diabetesâ€“associated complications: New ways to assess disease progression and evaluate therapy. <i>Proteomics - Clinical Applications</i> , 2008, 2, 997-1007.	0.8	64
279	CEâ€“MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. <i>Proteomics - Clinical Applications</i> , 2008, 2, 964-973.	0.8	178
280	Establishment of a European Network for Urine and Kidney Proteomics. <i>Journal of Proteomics</i> , 2008, 71, 490-492.	1.2	35
281	Human Proteinpedia enables sharing of human protein data. <i>Nature Biotechnology</i> , 2008, 26, 164-167.	9.4	155
282	Capillary electrophoresis mass spectrometry as a potential tool to detect lithium-induced nephropathy: Preliminary results. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 673-678.	2.5	7
283	Urine in Clinical Proteomics. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 1850-1862.	2.5	368
284	Exploring the Uremic Toxins Using Proteomic Technologies. , 2008, 160, 159-171.		19
285	Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 11299-11304.	3.3	151
286	Identification of Urinary Biomarkers by Proteomics in Newborns: Use in Obstructive Nephropathy. , 2008, 160, 127-141.		36
287	Urinary Proteomic Biomarkers in Coronary Artery Disease. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 290-298.	2.5	197
288	Capillary Electrophoresis Coupled to Mass Spectrometry for Biomarker Discovery and Diagnosis of Kidney Diseases. , 2008, 160, 107-126.		14

#	ARTICLE	IF	CITATIONS
289	Urinary Proteomics in Diabetes and CKD. Journal of the American Society of Nephrology: JASN, 2008, 19, 1283-1290.	3.0	267
290	Review on uraemic solutes II Variability in reported concentrations: causes and consequences. Nephrology Dialysis Transplantation, 2007, 22, 3115-3121.	0.4	49
291	Advances in Urinary Proteome Analysis and Biomarker Discovery. Journal of the American Society of Nephrology: JASN, 2007, 18, 1057-1071.	3.0	264
292	Body Fluid Proteomics for Biomarker Discovery: Lessons from the Past Hold the Key to Success in the Future. Journal of Proteome Research, 2007, 6, 4549-4555.	1.8	216
293	Proteomics of Human Urine. , 2007, , 225-268.		0
294	A database of naturally occurring human urinary peptides and proteins for use in clinical applications. Nature Precedings, 2007, , .	0.1	0
295	CE â€“ a multifunctional application for clinical diagnosis. Electrophoresis, 2007, 28, 1407-1417.	1.3	46
296	Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis, 2007, 28, 4469-4483.	1.3	83
297	Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics - Clinical Applications, 2007, 1, 148-156.	0.8	274
298	High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine. Proteomics - Clinical Applications, 2007, 1, 792-804.	0.8	55
299	Peptidomic analysis of rat urine using capillary electrophoresis coupled to mass spectrometry. Proteomics - Clinical Applications, 2007, 1, 650-660.	0.8	24
300	Grand Rounds in Proteomics at the FDA White Oak, Silver Spring, MD, USA, April 3, 2007. Proteomics - Clinical Applications, 2007, 1, 1526-1531.	0.8	10
301	Mass spectrometry based proteomics in urine biomarker discovery. World Journal of Urology, 2007, 25, 435-443.	1.2	59
302	Application of Proteomics to Posttransplantational Follow-Up. Methods in Molecular Medicine, 2007, 134, 217-227.	0.8	10
303	Proteomics of Human Dialysate and Ultrafiltrate Fluids Yielded by Renal Replacement Therapy. , 2007, , 509-520.		1
304	Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncology, The, 2006, 7, 230-240.	5.1	402
305	Analysis of complex, multidimensional datasets. Drug Discovery Today: Technologies, 2006, 3, 13-19.	4.0	30
306	Effects of oral vitaminâ€¦C supplementation in hemodialysis patients: A proteomic assessment. Proteomics, 2006, 6, 993-1000.	1.3	48

#	ARTICLE	IF	CITATIONS
307	High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. <i>Proteomics</i> , 2006, 6, 5615-5627.	1.3	95
308	Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. <i>Nature Medicine</i> , 2006, 12, 398-400.	15.2	248
309	Value of proteomics applied to the follow-up in stem cell transplantation. <i>Annals of Hematology</i> , 2006, 85, 205-211.	0.8	18
310	Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. <i>Electrophoresis</i> , 2006, 27, 2111-2125.	1.3	194
311	The molecular make-up of a tumour: proteomics in cancer research. <i>Clinical Science</i> , 2005, 108, 369-383.	1.8	97
312	Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. <i>Kidney International</i> , 2005, 67, 2313-2320.	2.6	203
313	Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. <i>Kidney International</i> , 2005, 68, 193-205.	2.6	126
314	Detection of Acute Tubulointerstitial Rejection by Proteomic Analysis of Urinary Samples in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 2479-2488.	2.6	134
315	Identification of urinary protein pattern in Type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. <i>Journal of Diabetes and Its Complications</i> , 2005, 19, 223-232.	1.2	111
316	Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. <i>Electrophoresis</i> , 2005, 26, 2797-2808.	1.3	151
317	Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: Towards new diagnostic and therapeutic approaches. <i>Electrophoresis</i> , 2005, 26, 1476-1487.	1.3	120
318	Capillary electrophoresis coupled to mass spectrometry for clinical diagnostic purposes. <i>Electrophoresis</i> , 2005, 26, 2708-2716.	1.3	98
319	Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. <i>Mass Spectrometry Reviews</i> , 2005, 24, 959-977.	2.8	275
320	Online coupling of capillary electrophoresis with mass spectrometry for the identification of biomarkers for clinical diagnosis. <i>Expert Review of Proteomics</i> , 2005, 2, 639-647.	1.3	39
321	Combined Top-Down and Bottom-Up Mass Spectrometric Approach to Characterization of Biomarkers for Renal Disease. <i>Analytical Chemistry</i> , 2005, 77, 7163-7171.	3.2	91
322	Mechanisms of Arginine-Vasopressin-Induced Ca ²⁺ Oscillations in β ² -Cells (HIT-T15): A Role for Oscillating Protein Kinase C. <i>Endocrinology</i> , 2004, 145, 4635-4644.	1.4	5
323	Proteomics: a novel tool to unravel the patho-physiology of uraemia. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 3068-3077.	0.4	121
324	Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. <i>Kidney International</i> , 2004, 65, 2426-2434.	2.6	189

#	ARTICLE	IF	CITATIONS
325	Activation of protein kinase A (PKA) by 8-Cl-cAMP as a novel approach for antileukaemic therapy. <i>British Journal of Cancer</i> , 2004, 91, 186-192.	2.9	18
326	Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2004, 18, 149-156.	0.7	186
327	Clinical proteomics: a question of technology. <i>Rapid Communications in Mass Spectrometry</i> , 2004, 18, 2365-2366.	0.7	28
328	Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use. <i>Electrophoresis</i> , 2004, 25, 2044-2055.	1.3	100
329	Differential polypeptide display: the search for the elusive target. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 803, 17-26.	1.2	33
330	Identification and analysis of phosphopeptides. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 803, 111-120.	1.2	65
331	Structural Mechanism for Lipid Activation of the Rac-Specific GAP, β 2-Chimaerin. <i>Cell</i> , 2004, 119, 407-418.	13.5	133
332	Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2004, 104, 340-349.	0.6	167
333	Proteomic analysis for the assessment of diabetic renal damage in humans. <i>Clinical Science</i> , 2004, 107, 485-495.	1.8	170
334	The V5 Domain of Protein Kinase C Plays a Critical Role in Determining the Isoform-Specific Localization, Translocation, and Biological Function of Protein Kinase C- δ and - μ . <i>Molecular Cancer Research</i> , 2004, 2, 129-140.	1.5	23
335	Capillary electrophoresis coupled to mass spectrometry to establish polypeptide patterns in dialysis fluids. <i>Journal of Chromatography A</i> , 2003, 1013, 157-171.	1.8	91
336	Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. <i>Journal of Chromatography A</i> , 2003, 1013, 173-181.	1.8	188
337	A Raf-1 Mutant That Dissociates MEK/Extracellular Signal-Regulated Kinase Activation from Malignant Transformation and Differentiation but Not Proliferation. <i>Molecular and Cellular Biology</i> , 2003, 23, 1983-1993.	1.1	51
338	Protein Kinase C δ Activation and Translocation to the Nucleus Are Required for Fatty Acid-Induced Apoptosis of Insulin-Secreting Cells. <i>Diabetes</i> , 2003, 52, 991-997.	0.3	134
339	Protein Kinase C δ Induces Src Kinase Activity via Activation of the Protein Tyrosine Phosphatase PTP β . <i>Journal of Biological Chemistry</i> , 2003, 278, 34073-34078.	1.6	84
340	Protein Kinase C Induces Actin Reorganization via a Src- and Rho-dependent Pathway. <i>Journal of Biological Chemistry</i> , 2002, 277, 20903-20910.	1.6	122
341	Induction of Apoptosis by Protein Kinase C δ Is Independent of Its Kinase Activity. <i>Journal of Biological Chemistry</i> , 2002, 277, 32054-32062.	1.6	45
342	Cyclic AMP-Dependent Kinase Regulates Raf-1 Kinase Mainly by Phosphorylation of Serine 259. <i>Molecular and Cellular Biology</i> , 2002, 22, 3237-3246.	1.1	202

#	ARTICLE	IF	CITATIONS
343	PKC δ Enhances Insulin-like Growth Factor 1-Dependent Mitogenic Activity in the Rat Clonal δ Cell Line RIN 1046-38. <i>Biochemical and Biophysical Research Communications</i> , 2002, 290, 85-90.	1.0	17
344	Phosphorylation of GRK2 by Protein Kinase C Abolishes Its Inhibition by Calmodulin. <i>Journal of Biological Chemistry</i> , 2001, 276, 1911-1915.	1.6	84
345	Identification of the smooth muscle-specific protein, sm22, as a novel protein kinase C substrate using two-dimensional gel electrophoresis and mass spectrometry. <i>Electrophoresis</i> , 2000, 21, 2443-2453.	1.3	14
346	The PKC targeting protein RACK1 interacts with the Epstein-Barr virus activator protein BZLF1. <i>FEBS Journal</i> , 2000, 267, 3891-3901.	0.2	47
347	Mechanism of Suppression of the Raf/MEK/Extracellular Signal-Regulated Kinase Pathway by the Raf Kinase Inhibitor Protein. <i>Molecular and Cellular Biology</i> , 2000, 20, 3079-3085.	1.1	357
348	The Raf-1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments. <i>FASEB Journal</i> , 2000, 14, 2008-2021.	0.2	55
349	Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation. <i>Journal of Biological Chemistry</i> , 2000, 275, 22300-22304.	1.6	200
350	beta 2-Chimaerin is a novel target for diacylglycerol: Binding properties and changes in subcellular localization mediated by ligand binding to its C1 domain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 11854-11859.	3.3	91
351	Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. <i>Nature</i> , 1999, 401, 173-177.	13.7	808
352	Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells. <i>EMBO Journal</i> , 1999, 18, 6973-6982.	3.5	111
353	Ectopic Expression of Protein Kinase C δ , ϵ , and ζ , but Not η or θ , Provide for Insulin Stimulation of Glucose Uptake in NIH-3T3 Cells. <i>Archives of Biochemistry and Biophysics</i> , 1999, 372, 69-79.	1.4	24
354	CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. <i>EMBO Journal</i> , 1998, 17, 6230-6240.	3.5	590
355	Regulation of Raf-1 kinase by TNF via its second messenger ceramide and cross-talk with mitogenic signalling. <i>EMBO Journal</i> , 1998, 17, 732-742.	3.5	99
356	The catalytic domain of PKC- δ , in reciprocal PKC- ϵ and δ chimeras, is responsible for conferring tumorigenicity to NIH3T3 cells, whereas both regulatory and catalytic domains of PKC- δ contribute to in vitro transformation. <i>Oncogene</i> , 1998, 16, 53-60.	2.6	23
357	ϵ -Protein Kinase C Phosphorylation Parallels Inhibition of Nerve Growth Factor-Induced Differentiation Independent of Changes in Trk A and MAP Kinase Signalling in PC12 Cells. <i>Cellular Signalling</i> , 1998, 10, 265-276.	1.7	7
358	Protein kinase C isoforms δ , ϵ and ζ require insulin receptor substrate-1 to inhibit the tyrosine kinase activity of the insulin receptor in human kidney embryonic cells (HEK 293 cells). <i>Diabetologia</i> , 1998, 41, 833-838.	2.9	105
359	Studies of perinuclear and nuclear translocation of the Raf-1 protein in rodent fibroblasts. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1998, 1402, 6-16.	1.9	1
360	Activation of bcl-2 suppressible 40 and 44 kDa p38-like kinases during apoptosis of early and late B lymphocytic cell lines. <i>FEBS Letters</i> , 1998, 427, 29-35.	1.3	3

#	ARTICLE	IF	CITATIONS
361	Activated Raf Induces the Hyperphosphorylation of Stathmin and the Reorganization of the Microtubule Network. <i>Journal of Biological Chemistry</i> , 1998, 273, 22848-22855.	1.6	43
362	Activation of the Epstein-Barr Virus Transcription Factor BZLF1 by 12- <i>O</i> -Tetradecanoylphorbol-13-Acetate-Induced Phosphorylation. <i>Journal of Virology</i> , 1998, 72, 8105-8114.	1.5	59
363	The Catalytic Domain of Protein Kinase C- δ in Reciprocal δ and ϵ Chimeras Mediates Phorbol Ester-induced Macrophage Differentiation of Mouse Promyelocytes. <i>Journal of Biological Chemistry</i> , 1997, 272, 76-82.	1.6	45
364	Inhibition of the Raf-1 Kinase by Cyclic AMP Agonists Causes Apoptosis of v-abl-Transformed Cells. <i>Molecular and Cellular Biology</i> , 1997, 17, 3229-3241.	1.1	70
365	Protein kinase C (PKC) μ enhances the inhibitory effect of TNF α on insulin signaling in HEK293 cells. <i>FEBS Letters</i> , 1997, 418, 119-122.	1.3	34
366	Protein kinase C isoforms δ 1 and δ 2 inhibit the tyrosine kinase activity of the insulin receptor. <i>Diabetologia</i> , 1997, 40, 863-866.	2.9	106
367	Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells. <i>Genes and Development</i> , 1996, 10, 1455-1466.	2.7	36
368	Characterization of β Kinases. <i>Journal of Biological Chemistry</i> , 1996, 271, 13868-13874.	1.6	62
369	Negative Regulation of Raf-1 by Phosphorylation of Serine 621. <i>Molecular and Cellular Biology</i> , 1996, 16, 5409-5418.	1.1	210
370	Cloning and characterisation of genes (pkc1 and pkcA) encoding protein kinase C homologues from <i>Trichoderma reesei</i> and <i>Aspergillus niger</i> . <i>Molecular Genetics and Genomics</i> , 1996, 250, 17-28.	2.4	21
371	P-88: Insulin-induced changes in alternative splicing of mRNA: A mechanism for enhancing insulin responsiveness. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1996, 104, 149-150.	0.6	0
372			

#	ARTICLE	IF	CITATIONS
379	Overexpression of Mammalian Protein Kinase C- δ Does Not Affect the Growth Characteristics of NIH 3T3 Cells. <i>Biochemical and Biophysical Research Communications</i> , 1995, 213, 266-272.	1.0	23
380	Identification of the primary growth response gene, ST2/T1, as a gene whose expression is differentially regulated by different protein kinase C isozymes. <i>FEBS Letters</i> , 1995, 372, 189-193.	1.3	7
381	Regulation of Raf-1 kinase activity by the 14-3-3 family of proteins. <i>EMBO Journal</i> , 1995, 14, 685-96.	3.5	44
382	Association of elevated levels of protein kinase C- δ mRNA and protein with murine B-lymphocytic neoplasia. <i>Molecular Carcinogenesis</i> , 1994, 11, 131-137.	1.3	4
383	Differential Role of Protein Kinase C in Cytokine Induced Lymphocyte-Endothelium Interaction In Vitro. <i>Scandinavian Journal of Immunology</i> , 1994, 40, 395-402.	1.3	15
384	Induction of plasmacytomas that secrete monoclonal anti-peptide antibodies by retroviral transformation. <i>Journal of Immunological Methods</i> , 1994, 168, 123-130.	0.6	6
385	Insulin-like Effects of Sodium Orthovanadate on Diacylglycerol-Protein Kinase C Signaling in BC3H-1 Myocytes. <i>Archives of Biochemistry and Biophysics</i> , 1994, 312, 167-172.	1.4	12
386	Assignment of the Protein Kinase C δ Polypeptide Gene (PRKCD) to Human Chromosome 3 and Mouse Chromosome 14. <i>Genomics</i> , 1994, 19, 161-162.	1.3	29
387	A protein kinase-encoding gene, pkl, from <i>Trichoderma reesei</i> , homologous to the yeast YPK1 and YPK2 (YKR2) genes. <i>Gene</i> , 1994, 146, 309-310.	1.0	9
388	Selective Involvement Of Protein Kinase C Isozymes In Differentiation And Neoplastic Transformation. <i>Advances in Cancer Research</i> , 1994, 64, 159-209.	1.9	92
389	Mechanism of inhibition of Raf-1 by protein kinase A.. <i>Molecular and Cellular Biology</i> , 1994, 14, 6696-6703.	1.1	310
390	Overexpressed protein kinase C-delta and -epsilon subtypes in NIH 3T3 cells exhibit differential subcellular localization and differential regulation of sodium-dependent phosphate uptake.. <i>Journal of Biological Chemistry</i> , 1994, 269, 4761-4766.	1.6	47
391	Tyrosine phosphorylation of protein kinase C-delta in response to its activation.. <i>Journal of Biological Chemistry</i> , 1994, 269, 2349-2352.	1.6	161
392	Zinc finger domains and phorbol ester pharmacophore. Analysis of binding to mutated form of protein kinase C zeta and the vav and c-raf proto-oncogene products. <i>Journal of Biological Chemistry</i> , 1994, 269, 11590-11594.	1.6	108
393	Mechanism of Inhibition of Raf-1 by Protein Kinase A. <i>Molecular and Cellular Biology</i> , 1994, 14, 6696-6703.	1.1	112
394	Tyrosine phosphorylation of protein kinase C-delta in response to its activation. <i>Journal of Biological Chemistry</i> , 1994, 269, 2349-52.	1.6	146
395	Zinc finger domains and phorbol ester pharmacophore. Analysis of binding to mutated form of protein kinase C zeta and the vav and c-raf proto-oncogene products. <i>Journal of Biological Chemistry</i> , 1994, 269, 11590-4.	1.6	99
396	Protein kinase C δ activates RAF-1 by direct phosphorylation. <i>Nature</i> , 1993, 364, 249-252.	13.7	1,297

#	ARTICLE	IF	CITATIONS
397	Unique expression pattern of protein kinase C- δ ; high mRNA levels in normal mouse testes and in T-lymphocytic cells and neoplasms. <i>FEBS Letters</i> , 1993, 326, 51-55.	1.3	43
398	Effects of insulin and phorbol esters on MARCKS (myristoylated alanine-rich C-kinase substrate) phosphorylation (and other parameters of protein kinase C activation) in rat adipocytes, rat soleus muscle and BC3H-1 myocytes. <i>Biochemical Journal</i> , 1993, 295, 155-164.	1.7	33
399	Addition of constitutive c-myc expression to Abelson murine leukemia virus changes the phenotype of the cells transformed by the virus from pre-B-cell lymphomas to plasmacytomas.. <i>Molecular and Cellular Biology</i> , 1993, 13, 2578-2585.	1.1	12
400	Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity.. <i>Journal of Biological Chemistry</i> , 1993, 268, 6090-6096.	1.6	490
401	Ca(2+)-dependent and Ca(2+)-independent isozymes of protein kinase C mediate exocytosis in antigen-stimulated rat basophilic RBL-2H3 cells. Reconstitution of secretory responses with Ca2+ and purified isozymes in washed permeabilized cells.. <i>Journal of Biological Chemistry</i> , 1993, 268, 1749-1756.	1.6	339
402	Selective inhibition of protein kinase C isozymes by the indolocarbazole GÅ¶ 6976. <i>Journal of Biological Chemistry</i> , 1993, 268, 9194-9197.	1.6	1,454
403	Phorbol ester-induced myeloid differentiation is mediated by protein kinase C-alpha and -delta and not by protein kinase C-beta II, -epsilon, -zeta, and -eta.. <i>Journal of Biological Chemistry</i> , 1993, 268, 20110-20115.	1.6	233
404	Addition of Constitutive c- <i>myc</i> Expression to Abelson Murine Leukemia Virus Changes the Phenotype of the Cells Transformed by the Virus from Pre-B-Cell Lymphomas to Plasmacytomas. <i>Molecular and Cellular Biology</i> , 1993, 13, 2578-2585.	1.1	5
405	Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. <i>Molecular Pharmacology</i> , 1993, 44, 298-307.	1.0	240
406	Phorbol ester-induced myeloid differentiation is mediated by protein kinase C-alpha and -delta and not by protein kinase C-beta II, -epsilon, -zeta, and -eta. <i>Journal of Biological Chemistry</i> , 1993, 268, 20110-5.	1.6	198
407	Ca(2+)-dependent and Ca(2+)-independent isozymes of protein kinase C mediate exocytosis in antigen-stimulated rat basophilic RBL-2H3 cells. Reconstitution of secretory responses with Ca2+ and purified isozymes in washed permeabilized cells. <i>Journal of Biological Chemistry</i> , 1993, 268, 1749-56.	1.6	300
408	Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. <i>Journal of Biological Chemistry</i> , 1993, 268, 6090-6.	1.6	420
409	Selective inhibition of protein kinase C isozymes by the indolocarbazole GÅ¶ 6976. <i>Journal of Biological Chemistry</i> , 1993, 268, 9194-7.	1.6	1,286
410	The cDNA sequence, expression pattern and protein characteristics of mouse protein kinase C- δ . <i>Gene</i> , 1992, 122, 305-311.	1.0	53
411	Transcripts encoding protein kinase C- δ , - μ , - η , and - ζ are expressed in basal and differentiating mouse keratinocytes in vitro and exhibit quantitative changes in neoplastic cells. <i>Molecular Carcinogenesis</i> , 1992, 5, 286-292.	1.3	105
412	Mouse protein kinase C-delta., the major isoform expressed in mouse hemopoietic cells: sequence of the cDNA, expression patterns, and characterization of the protein. <i>Biochemistry</i> , 1991, 30, 7925-7931.	1.2	90
413	Induction of plasmacytomas secreting antigen-specific monoclonal antibodies with a retrovirus expressing v-abl and c-myc.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 8735-8739.	3.3	20
414	Expression of protein kinase C genes in hemopoietic cells is cell-type- and B cell-differentiation stage specific. <i>Journal of Immunology</i> , 1991, 147, 3981-7.	0.4	109

#	ARTICLE	IF	CITATIONS
415	Probing structure and function of the raf protein kinase domain with monoclonal antibodies. <i>Oncogene</i> , 1990, 5, 713-20.	2.6	35
416	A monoclonal antibody against the alkaline extracellular Î²-glucosidase from <i>Trichoderma reesei</i> : reactivity with other <i>Trichoderma</i> Î²-glucosidases. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1989, 992, 298-306.	1.1	21
417	Monoclonal antibodies against different domains of cellobiohydrolase I and II from <i>Trichoderma reesei</i> . <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1989, 990, 1-7.	1.1	81
418	Characteristics of the minor group receptor of human rhinoviruses. <i>Virology</i> , 1988, 163, 19-25.	1.1	31
419	Detection of the Human Rhinovirus Minor Group Receptor on Renaturing Western Blots. <i>Journal of General Virology</i> , 1988, 69, 2653-2656.	1.3	32
420	Formation and location of glucose oxidase in citric acid producing mycelia of <i>Aspergillus niger</i> . <i>Applied Microbiology and Biotechnology</i> , 1985, 21-21, 27.	1.7	35
421	Effect of manganese deficiency on plasma-membrane lipid composition and glucose uptake in <i>Aspergillus niger</i> . <i>FEMS Microbiology Letters</i> , 1985, 26, 271-274.	0.7	27
422	Citrate inhibition of glucose uptake in <i>Aspergillus niger</i> . <i>Biotechnology Letters</i> , 1984, 6, 425-430.	1.1	24
423	Biomarker Discovery. , 0, , 317-339.		0
424	Peptidomics Approach to Proteomics. , 0, , 153-175.		1